An observational study in The Impact of COVID19 on Psoriasis Patients, sponsored by Cairo University. Status unknown. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2022-05-19.
Sponsored by Cairo University · Observational
The main objective of this work is to investigate the effect of COVID-19 pandemic on psoriasis patients.
This work is designed as a cross-sectional survey based on a questionnaire directed to Egyptian psoriasis patients.
7,641 studies on the registry are indexed under COVID-19; 487 are open to participants now.
This study's planned enrollment of 230 is below the median of 261 across 3,136 observational studies indexed under COVID-19.
Browse COVID-19 studies →Cairo University is the lead sponsor of 4,780 studies on the registry; 1,427 are open to participants now.
Of its 36 completed or terminated interventional studies of FDA-regulated products, 5 (14%) have results posted.
Counted across the registry records on this site, refreshed daily.
Psoriasis patients
Exclusion Criteria:
Questionnaire to assess the impact of COVID 19 on psoriasis patients
Questionnaire
To assess the effect of COVID 19 on psoriasis disease, treatment, follow up, vaccine
Time frame: 2-4 weeks
No study locations are listed for this record.
This study is status unknown, as verified in May 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Cairo University